NCT00470405View on ClinicalTrials.gov

Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2007

Study Completion Date

November 30, 2007

Conditions
LymphomaSolid Tumor
Interventions
DRUG

oxaliplatin

75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle

DRUG

pemetrexed disodium

a novel antifolate with multiple targets.

Trial Locations (1)

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00470405 - Pemetrexed and Oxaliplatin in Treating Patients With Metastatic Solid Tumors or Lymphoma | Biotech Hunter | Biotech Hunter